SCHEMBL14859304

SCHEMBL14859304

Cc1ccc(C(=O)NC(=O)N(S)Cc2ccc(Cl)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.56
▸ SCN5A Q14524 1/20 0.52
▸ SCN2A Q99250 1/20 0.52
▸ HTT P42858 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ ALOX12 P18054 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ NPC1 O15118 4/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.48
▸ PTGS2 P35354 1/20 0.47
▸ KMT2A Q03164 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ CES2 O00748 1/20 0.45
▸ CES1 P23141 1/20 0.45
▸ TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6347548 0.76 ALDH1A1 (0.47) RAB9AHTTSMN1; SMN2MAPTCYP2C9
SCHEMBL14859929 0.72 ALDH1A1 (0.42) RAB9ASCN5ASCN2AHTTSMN1; SMN2
SCHEMBL25872270 0.72 MEN1 (0.72) RAB9AHTTSMN1; SMN2MAPTCYP2C19
SCHEMBL13947380 0.72 MEN1 (0.72) RAB9AHTTSMN1; SMN2MAPTCYP2C19
SCHEMBL14859303 0.71 KMT2A (0.75) RAB9AHTTSMN1; SMN2MAPTCYP3A4
SCHEMBL30131238 0.71 MMP13 (0.58) RAB9AHTTMAPTNPC1L3MBTL1
SCHEMBL14859722 0.70 NPC1 (0.40) RAB9ASCN5ASCN2AHTTSMN1; SMN2
SCHEMBL4628432 0.69 SCN5A (0.57) RAB9ASCN5ASCN2AHTTSMN1; SMN2
SCHEMBL3954739 0.69 ALDH1A1 (0.55) RAB9ASMN1; SMN2MAPTNPC1KMT2A
SCHEMBL4628439 0.68 SCN2A (1.00) RAB9ASCN5ASCN2ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP claimed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US claimed
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP disclosed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT UGP2, TPMT, UPP1 RAB9A 2456/4885SCN5A 3909/4885SCN2A 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback